| Jeffrey R Nichols, DO | |
|
1000 Mineral Point Ave, Janesville, WI 53548 | |
| (608) 756-6611 | |
| (608) 756-6177 |
| Full Name | Jeffrey R Nichols |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 1000 Mineral Point Ave, Janesville, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316334683 | NPI | - | NPPES |
| 1316334683 | Medicaid | WI | |
| 1316334683 | Other | WI | BCBSWI |
| 4919 | Other | WI | MERCYCARE INSURANCE |
| K400494086 | Other | WI | WI MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Health System Corp | Janesville, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health System Corporation | 7416860440 | 459 |
News Archive
Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.
Scientists have discovered that a high fat, low carbohydrate diet improves Alzheimer's disease in mice and say the study results may also have implications for dieters.
Scientists at the University of Nottingham have developed an ultrasonic imaging system, which can be deployed on the tip of a hair-thin optical fiber, and will be insertable into the human body to visualize cell abnormalities in 3D.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the presentation of clinical and non-clinical data on its lead product candidate, CRLX101, at the 2011 AACR-NCI-EORTC International Conference taking place from November 12-16 in San Francisco, California.
› Verified 2 days ago
| Entity Name | Mercy Health System Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598718603 PECOS PAC ID: 7416860440 Enrollment ID: O20031113000164 |
News Archive
Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.
Scientists have discovered that a high fat, low carbohydrate diet improves Alzheimer's disease in mice and say the study results may also have implications for dieters.
Scientists at the University of Nottingham have developed an ultrasonic imaging system, which can be deployed on the tip of a hair-thin optical fiber, and will be insertable into the human body to visualize cell abnormalities in 3D.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the presentation of clinical and non-clinical data on its lead product candidate, CRLX101, at the 2011 AACR-NCI-EORTC International Conference taking place from November 12-16 in San Francisco, California.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey R Nichols, DO 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 756-6611 | Jeffrey R Nichols, DO 1000 Mineral Point Ave, Janesville, WI 53548 Ph: (608) 756-6611 |
News Archive
Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.
Scientists have discovered that a high fat, low carbohydrate diet improves Alzheimer's disease in mice and say the study results may also have implications for dieters.
Scientists at the University of Nottingham have developed an ultrasonic imaging system, which can be deployed on the tip of a hair-thin optical fiber, and will be insertable into the human body to visualize cell abnormalities in 3D.
Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the presentation of clinical and non-clinical data on its lead product candidate, CRLX101, at the 2011 AACR-NCI-EORTC International Conference taking place from November 12-16 in San Francisco, California.
› Verified 2 days ago
Michael J. Hartmann, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6111 Fax: 608-756-6177 | |
Dr. Michael V Coogan, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6000 | |
Sean William Marquis, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6611 Fax: 608-756-6177 | |
Dr. Karl A Nibbelink, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6611 | |
Christopher M. Koenig, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6611 Fax: 608-756-6177 | |
Dr. Martin Fedko, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Mineral Point Ave, Janesville, WI 53548 Phone: 608-756-6611 Fax: 608-756-6177 | |
Stephen L Merrill, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3524 E Milwaukee St, Janesville, WI 53546 Phone: 608-756-7100 Fax: 608-756-4700 |